Targovax Presented ONCOS-102 Poster at 13th International Adenovirus Meeting

News provided by

Oct 01, 2018, 06:50 ET

OSLO, Norway, Oct. 1, 2018 /PRNewswire/ --

Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, announces that the Company presented at the following conference:

13th International Adenovirus Meeting
Date: 27 September 2018
Presenter: Lukasz Kuryk, Director Clinical Science
Poster session: 20:00 – 23:00
Venue: San José Vista Hermosa, Mexico

Abstract title: "Anti-tumor specific T-cell responses induced by oncolytic adenovirus ONCOS-102 in peritoneal mesothelioma mouse model"
Please see the poster below:

1809 Poster ONCOS-102

Contact:

For further information, please contact:
Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: [email protected]

Media and IR enquires:
Andreas Tinglum - Corporate Communications (Norway)
Phone: +47 9300 1773
Email: [email protected]

Simon Conway/Stephanie Cuthbert - FTI Consulting (International)
Phone: +44 20 3727 1000
Email: [email protected]